Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP)

Detalles Bibliográficos
Autores principales: Fröbe, Ana, Murgić, Jure, Rauh, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070301/
https://www.ncbi.nlm.nih.gov/pubmed/27843608
http://dx.doi.org/10.1136/esmoopen-2016-000049
_version_ 1782461118018486272
author Fröbe, Ana
Murgić, Jure
Rauh, Stefan
author_facet Fröbe, Ana
Murgić, Jure
Rauh, Stefan
author_sort Fröbe, Ana
collection PubMed
description
format Online
Article
Text
id pubmed-5070301
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50703012016-11-14 Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP) Fröbe, Ana Murgić, Jure Rauh, Stefan ESMO Open Correspondence BMJ Publishing Group 2016-05-17 /pmc/articles/PMC5070301/ /pubmed/27843608 http://dx.doi.org/10.1136/esmoopen-2016-000049 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Correspondence
Fröbe, Ana
Murgić, Jure
Rauh, Stefan
Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP)
title Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP)
title_full Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP)
title_fullStr Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP)
title_full_unstemmed Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP)
title_short Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP)
title_sort single institution long-term efficacy and safety analysis of abiraterone acetate (aa) in the treatment of patients with metastatic castration-resistant prostate cancer (mcrpc) in a named patient programme (npp)
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070301/
https://www.ncbi.nlm.nih.gov/pubmed/27843608
http://dx.doi.org/10.1136/esmoopen-2016-000049
work_keys_str_mv AT frobeana singleinstitutionlongtermefficacyandsafetyanalysisofabirateroneacetateaainthetreatmentofpatientswithmetastaticcastrationresistantprostatecancermcrpcinanamedpatientprogrammenpp
AT murgicjure singleinstitutionlongtermefficacyandsafetyanalysisofabirateroneacetateaainthetreatmentofpatientswithmetastaticcastrationresistantprostatecancermcrpcinanamedpatientprogrammenpp
AT rauhstefan singleinstitutionlongtermefficacyandsafetyanalysisofabirateroneacetateaainthetreatmentofpatientswithmetastaticcastrationresistantprostatecancermcrpcinanamedpatientprogrammenpp

Ejemplares similares